Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Pemetrexed 4Spinal Puncture 3Radiotherapy 3aflutinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Bevacizumab 2toripalimab 1sintilimab 1pertuzumab 1lorlatinib 1azeliragon 1adavosertib 1Trastuzumab 1Referral and Consultation 1Radiation 1Physical Examination 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1GDC-0084 1Drug Therapy 1Deferoxamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × lorlatinib × 90 days × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡